How it works, simply
It combines amylin and GLP-1 signaling in one molecule.
What the evidence tells us
The newer name does not mean it is an approved product; formulation-specific trial results matter.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Combines amylin and GLP-1 receptor agonism in one investigational asset.
Sponsor or developer: Novo Nordisk
Studied or labeled topics: Obesity, Type 2 diabetes
2026-08-05: Sponsor update describes the Phase 3 AMAZE obesity program and planned diabetes development.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- Novo Nordisk: 2026 second-quarter presentation ↗ · Sponsor · 2026-08-05
Readability updated October 10, 2026. Evidence review: September 23, 2026 (listed facts only). A wording update is not a new clinical review.